CoChat
Sign Up
Cited by 43

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Sequential screening nominates the Parkinson's disease associated kinase LRRK2 as a regulator of Clathrin-mediated endocytosis

Heaton, George R., Landeck, Natalie, Mamais, Adamantios, Nalls, Mike A., Nixon-Abell, Jonathon, Kumaran, Ravindran, Beilina, Alexandra, Pellegrini, Laura, Li, Yan, Harvey, Kirsten, Cookson, Mark R.·2020·Neurobiology of Disease
DOI 10.1016/j.nbd.2020.104948PMC PMC7339134

Published version of a preprint

Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2020.104948

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • LRRK2 activity plays a role in synaptic vesicle endocytosis, activation of autophagy, and axonal transport of growth factor receptors.

    “LRRK2 activity plays a role in synaptic vesicle endocytosis, activation of autophagy, and axonal transport of growth factor receptors [2, 7, 10, 24, 25, 36, 51, 59, 62, 75, 77, 96].”

    From Cellular and subcellular localization of Rab10 and phospho-T73 Rab10 in the mouse and human brain (2023) · cites this paper as [24]

    The Results report reduced synaptic endocytosis in neurons carrying an LRRK2 mutation, supporting a role in synaptic vesicle endocytosis. The Discussion mentions altered autophagic activity in LRRK2-knockout kidneys and trafficking of EGFR, but does not establish activation of autophagy or axonal transport of growth factor receptors. Page numbers are unavailable in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 55

  1. Abeliovich, 2016, Defects in trafficking bridge Parkinson’s disease pathology and genetics, Nature, 539, 207, 10.1038/nature20414 · DOI · Paper page
  2. Arranz, 2014, LRRK2 functions in synaptic vesicle endocytosis through a kinase-dependent mechanism, J. Cell Sci., 541
  3. Beilina, 2005, Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability, Proc. Natl. Acad. Sci., 102, 5703, 10.1073/pnas.0500617102 · DOI
  4. Beilina, 2014, Unbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson disease, Proc. Natl. Acad. Sci. U. S. A., 111, 2626, 10.1073/pnas.1318306111 · DOI · Paper page
  5. Boucrot, 2010, Roles of AP-2 in clathrin-mediated endocytosis, PLoS One, 5, 10.1371/journal.pone.0010597 · DOI
  6. Chia, 2014, Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7, Nat. Commun., 5, 5827, 10.1038/ncomms6827 · DOI
  7. Conner, 2003, Differential requirements for AP-2 in clathrin-mediated endocytosis, J. Cell Biol., 162, 773, 10.1083/jcb.200304069 · DOI · Paper page
  8. Connor-Robson, 2019, An integrated transcriptomics and proteomics analysis reveals functional endocytic dysregulation caused by mutations in LRRK2, Neurobiol. Dis., 127, 512, 10.1016/j.nbd.2019.04.005 · DOI
  9. Cookson, 2010, The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson’s disease, Nat. Rev. Neurosci., 11, 791, 10.1038/nrn2935 · DOI
  10. Cookson, 2015, LRRK2 pathways leading to neurodegeneration, Curr. Neurol. Neurosci. Rep., 15, 564, 10.1007/s11910-015-0564-y · DOI
  11. Daher, 2015, Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration, J. Biol. Chem., 290, 19433, 10.1074/jbc.M115.660001 · DOI
  12. Elkin, 2016, Endocytic pathways and endosomal trafficking: a primer, Wien. Med. Wochenschr., 166, 196, 10.1007/s10354-016-0432-7 · DOI
  13. Euesden, 2015, PRSice: polygenic risk score software, Bioinformatics, 31, 1466, 10.1093/bioinformatics/btu848 · DOI
  14. Fingerhut, 2001, Binding of AP2 to sorting signals is modulated by AP2 phosphorylation, J. Biol. Chem., 276, 5476, 10.1074/jbc.M009516200 · DOI
  15. Gaffield, 2007, Imaging synaptic vesicle exocytosis and endocytosis with FM dyes, Nat. Protoc., 1, 2916, 10.1038/nprot.2006.476 · DOI
  16. Gilsbach, 2014, Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation, Front. Mol. Neurosci., 7, 32, 10.3389/fnmol.2014.00032 · DOI
  17. Gómez-Suaga, 2014, LRRK2 delays degradative receptor trafficking by impeding late endosomal budding through decreasing Rab7 activity, Hum. Mol. Genet., 23, 1, 10.1093/hmg/ddu395 · DOI · Paper page
  18. Greggio, 2006, Kinase activity is required for the toxic effects of mutant LRRK2/dardarin, Neurobiol. Dis., 23, 329, 10.1016/j.nbd.2006.04.001 · DOI · Paper page
  19. Guaitoli, 2016, Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts, Proc. Natl. Acad. Sci., 113, E4357, 10.1073/pnas.1523708113 · DOI
  20. Jung, 2007, Clathrin-mediated endocytosis at synapses, Traffic, 8, 1129, 10.1111/j.1600-0854.2007.00595.x · DOI
  21. Kaksonen, 2018, Mechanisms of clathrin-mediated endocytosis, Nat. Rev. Mol. Cell Biol., 19, 313, 10.1038/nrm.2017.132 · DOI · Paper page
  22. Kalia, 2015, Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease, JAMA Neurol., 72, 100, 10.1001/jamaneurol.2014.2704 · DOI
  23. Kett, 2012, Leucine-rich repeat kinase 2 for beginners: six key questions, Cold Spring Harb. Perspect. Med., 2, a009407, 10.1101/cshperspect.a009407 · DOI
  24. Kumari, 2010, Leucine-rich repeat kinase 2-linked Parkinson’s disease: clinical and molecular findings, J. Mov. Disord., 3, 25, 10.14802/jmd.10008 · DOI
  25. Kuwahara, 2016, LRRK2 and RAB7L1 coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts, Sci. Rep., 6, 1, 10.1038/srep29945 · DOI · Paper page
  26. Lewis, 2009, The function of ROCO proteins in health and disease, Biol. Cell., 101, 183, 10.1042/BC20080053 · DOI
  27. Lewis, 2007, The R1441C mutation of LRRK2 disrupts GTP hydrolysis, Biochem. Biophys. Res. Commun., 357, 668, 10.1016/j.bbrc.2007.04.006 · DOI
  28. Liu, 2018, LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network, Hum. Mol. Genet., 27, 385, 10.1093/hmg/ddx410 · DOI · Paper page
  29. MacLeod, 2013, RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson’s disease risk, Neuron, 77, 425, 10.1016/j.neuron.2012.11.033 · DOI · Paper page
  30. Manzoni, 2015, Computational analysis of the LRRK2 interactome, PeerJ, 3, 10.7717/peerj.778 · DOI
  31. Matta, 2012, LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis, Neuron, 75, 1008, 10.1016/j.neuron.2012.08.022 · DOI · Paper page
  32. Mitsunari, 2005, Clathrin adaptor AP-2 is essential for early embryonal development, Mol. Cell. Biol., 25, 9318, 10.1128/MCB.25.21.9318-9323.2005 · DOI
  33. Nalls, 2019, Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies, Lancet Neurol., 18, 1091, 10.1016/S1474-4422(19)30320-5 · DOI · Paper page
  34. Nalls, 2019, Expanding Parkinson’s disease genetics: novel risk loci, genomic context, causal insights and heritable risk, bioRxiv, 388165
  35. Nguyen, 2017, Understanding the GTPase activity of LRRK2: regulation, function, and neurotoxicity, Adv. Neurobiol., 14, 71, 10.1007/978-3-319-49969-7_4 · DOI
  36. Nguyen, 2018, LRRK2 phosphorylation of auxilin mediates synaptic defects in dopaminergic neurons from patients with Parkinson’s disease, Proc. Natl. Acad. Sci., 115, 5576, 10.1073/pnas.1717590115 · DOI
  37. Olusanya, 2001, Phosphorylation of threonine 156 of the μ2 subunit of the AP2 complex is essential for endocytosis in vitro and in vivo, Curr. Biol., 11, 896, 10.1016/S0960-9822(01)00240-8 · DOI
  38. Pan, 2017, Parkinson’s disease-associated LRRK2 hyperactive kinase mutant disrupts synaptic vesicle trafficking in ventral midbrain neurons, J. Neurosci., 37, 11366, 10.1523/JNEUROSCI.0964-17.2017 · DOI · Paper page
  39. Pellegrini, 2018, Proteomic analysis reveals co-ordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice, Hum. Mol. Genet., 27, 3257, 10.1093/hmg/ddy232 · DOI
  40. Piccoli, 2011, LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool, J. Neurosci., 31, 2225, 10.1523/JNEUROSCI.3730-10.2011 · DOI
  41. Purlyte, 2017, Rab29 activation of the Parkinson’s disease-associated LRRK2 kinase, EMBO J., 37
  42. Ricotta, 2002, Phosphorylation of the AP2 μ subunit by AAK1 mediates high affinity binding to membrane protein sorting signals, J. Cell Biol., 156, 791, 10.1083/jcb.200111068 · DOI
  43. Rivero-Ríos, 2019, The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A, J. Biol. Chem., 294, 4738, 10.1074/jbc.RA118.005008 · DOI · Paper page
  44. Roosen, 2016, LRRK2 at the interface of autophagosomes, endosomes and lysosomes, Mol. Neurodegener., 11, 1, 10.1186/s13024-016-0140-1 · DOI
  45. Schreij, 2014, LRRK2 localizes to endosomes and interacts with clathrin-light chains to limit Rac1 activation, EMBO Rep., 16, 79, 10.15252/embr.201438714 · DOI
  46. Semerdjieva, 2008, Coordinated regulation of AP2 uncoating from clathrin-coated vesicles by rab5 and hRME-6, J. Cell Biol., 183, 499, 10.1083/jcb.200806016 · DOI
  47. Shin, 2008, LRRK2 regulates synaptic vesicle endocytosis, Exp. Cell Res., 314, 2055, 10.1016/j.yexcr.2008.02.015 · DOI
  48. Simon-Sanchez, 2009, Genome-wide association study reveals genetic risk underlying Parkinson’s disease, Genet, 41, 1308
  49. Singleton, 2011, A generalizable hypothesis for the genetic architecture of disease: pleomorphic risk loci, Hum. Mol. Genet., 20, 158, 10.1093/hmg/ddr358 · DOI
  50. Steger, 2016, Phosphoproteomics reveals that Parkinson’s disease kinase LRRK2 regulates a subset of Rab GTPases, Elife, 5, 10.7554/eLife.12813 · DOI · Paper page
  51. Steger, 2017, Systematic proteomic analysis of LRRK2-mediated rab GTPase phosphorylation establishes a connection to ciliogenesis, Elife, 6, 1, 10.7554/eLife.31012 · DOI · Paper page
  52. Tong, 2010, Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of -synuclein, and apoptotic cell death in aged mice, Proc. Natl. Acad. Sci., 107, 9879, 10.1073/pnas.1004676107 · DOI
  53. West, 2005, Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity, Proc. Natl. Acad. Sci. U. S. A., 102, 16842, 10.1073/pnas.0507360102 · DOI · Paper page
  54. Yao, 2013, Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity, Hum. Mol. Genet., 22, 328, 10.1093/hmg/dds431 · DOI
  55. Yun, 2015, An early endosome regulator, Rab5b, is an LRRK2 kinase substrate, J. Biochem., 157, 485, 10.1093/jb/mvv005 · DOI

Cited by

Sorted by citations

Metadata

Authors
Heaton, G. R., Landeck, N., Mamais, A., Nalls, M. A., Nixon-Abell, J., Kumaran, R., Beilina, A., Pellegrini, L., Li, Y., Harvey, K., & Cookson, M. R.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2020-07
Volume
141
Pages
104948
ISSN
0969-9961
DOI
10.1016/j.nbd.2020.104948
PMC
PMC7339134
Cited by
43
References
3
Language
en
Licence
Funders
  • Wellcome Trust
  • Medical Research Council
  • National Institute on Aging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review